Plants and the Political Economy of Chavín de Huántar

departmental bulletin pape

Follow-up for Patients with Obstructive Sleep Apnea Syndrome using A Portable Recording Device

2007-01A home screening device, LT-200, can record data on both breathing conditions and body positions during sleep for up to 3 consecutive days in patients with obstructive sleep apnea (OSAS). We investigated the usefulness of the LT-200 device for follow-up of OSAS. Eighteen patients (age 51.0±10.8 years, mean±SD) were enrolled in this study. Standard polysomnography (PSG) was performed on all patients. The number of apnea/hypopnea episodes per hour (apnea/hypopnea index: AHI), the total time that nocturnal oxygen saturation was <90% (oxygen desaturation time: ODT), and the minimum oxygen saturation during sleep (lowest Spo_2) were calculated. We used the LT-200 and PSG to evaluate any improvement in the data obtained after auto-continuous positive airway pressure (auto-CPAP) therapy. AHI was also measured using the LT-200 in three sleep positions to evaluate the efficacy of the lateral position. AHI, ODT, and lowest Spo_2 values did not differ significantly between the PSG and LT-200 recordings on the control and therapy nights. The LT-200 recordings showed that AHI, ODT, and lowest Spo_2 tended to be better on the second night of auto-CPAP therapy than on the first. AHI was significantly lower in the right and left lateral sleep positions than that in the supine position. Our findings suggest that since the LT-200 device provides important information about the severity of OSAS, the efficacy of auto-CPAP therapy, and body position under unattended conditions in the home. It may prove to be a useful tool for following up patients.departmental bulletin pape

通常の学級における特別支援教育を推進するための 担任への支援の在り方 ―小学校教員へのインタビューから―

text紀要論文 / Departmental Bulletin Paperdepartmental bulletin pape

ゲンチョ ハンソク ガンメン ケイレン ノ シュジュツ セイセキ オ サユウスル インシ ノ リンショウテキ ケントウ

半側顔面痙攣に対する神経血管減圧術はその高い治癒率から現在その治療法はほぼ確立された。しかし未だに手術効果の不完全な例も有り,これについて検討した報告例はまだ見あたらない。今回我々は半側顔面痙攣に対して行った神経血管減圧術例40例の追跡調査を行い手術効果の不完全な例に注目し,手術成績を左右する因子を把握する目的で種々な観点から検討を行った。検討した因子は既往歴,年齢,罹病期間,術前のfacial nerve blockの有無,術前,術中及び術後聴性脳幹反応の比較,圧迫血管の種類,及び術後合併症の7項目とした。手術結果は追跡調査結果より4型に分類された。顔面痙攣の残存した例は40例中9例で,術前の程度と比較すると1例が完全に再発したのみで残りの8例の残存度は術前の半分以下で平均32%であった。これらの顔面痙攣が残存した例と消失した31例とを7つの因子について比較検討した結果,年齢が60歳以上の16例中顔面痙攣が残存した例は7例であり,統計学的有意差を認めた(P<0.05)。また,年齢が60歳以上で尚かつ罹病期間が6年以上の12例中6例に残存を認め P<0.025で明かな有意差を認めた。他の5つの因子については明かな有意差が認められなかった。以上より顔面痙攣に対する神経血管減圧術の効果は,手術年齢及び罹病期間に左右され,これは顔面痙攣患者の手術時期の一つの目安となり,血管が神経を圧迫する時間的あるいは血管の器質的関係,更に神経の可塑性によると考えられた。journal articl

Search for B-→J/ψΛp̅ decay

journal articl

A Thought on Trial Productions of Arithmetic and Logic Circuits

departmental bulletin pape

CT-proET-1-, MR-proADM, and the calculated ratio in surviving as compared to nonsurviving patients

Data from all patients on admission are shown. Squares denote median values, boxes represent 25th to 75th percentiles and whiskers indicate the range.<p><b>Copyright information:</b></p><p>Taken from "Circulating Precursor Levels of Endothelin-1 and Adrenomedullin, Two Endothelium-Derived, Counteracting Substances, in Sepsis"</p><p></p><p>Endothelium 2007;14(6):345-351.</p><p>Published online 13 Dec 2007</p><p>PMCID:PMC2430170.</p><p></p

Receiver operating curve (ROC) analysis of CT-proET1, MRproADM, the CT-proET1/MR-proADM ratio and the APACHE II score with respect to outcome prediction of critically ill patients

Receiver operating characteristic (ROC) plots are graphical plots illustrating the sensitivity (-axis) and the specificity ( -axis) for all cut-off points of a diagnostic or prognostic test. The overall performance and a summary measure of the diagnostic accuracy of a test can be expressed as the area under the ROC curve (AUC). Note that an AUCof 0.50 means that the diagnostic accuracy in question is equivalent to that which would be obtained by flipping a coin (i.e., random chance). () Data of all patients ( = 95) with SIRS and sepsis on admission to the ICU. Sensitivity was calculated with nonsurvivors ( = 21), specificity with survivors ( = 74) during their hospital stay. () Data of patients with sepsis (including septic shock) in need for blood pressure support with vasoactiva ( = 30) on admission to the ICU. Sensitivity was calculated with nonsurvivors ( = 9), specificity with survivors ( = 21) during their hospital stay.<p><b>Copyright information:</b></p><p>Taken from "Circulating Precursor Levels of Endothelin-1 and Adrenomedullin, Two Endothelium-Derived, Counteracting Substances, in Sepsis"</p><p></p><p>Endothelium 2007;14(6):345-351.</p><p>Published online 13 Dec 2007</p><p>PMCID:PMC2430170.</p><p></p

CT-proET-1 and MR-proADM values in all patients according to the severity of disease

Patients' data on admission to the ICU were grouped according to the severity of the disease following consensus criteria in groups with “SIRS, but no sepsis,” “sepsis,” and “septic shock.” Squares denote median values and whiskers indicate 25th and 75th percentiles.<p><b>Copyright information:</b></p><p>Taken from "Circulating Precursor Levels of Endothelin-1 and Adrenomedullin, Two Endothelium-Derived, Counteracting Substances, in Sepsis"</p><p></p><p>Endothelium 2007;14(6):345-351.</p><p>Published online 13 Dec 2007</p><p>PMCID:PMC2430170.</p><p></p

Data_Sheet_3_Hyponatremia Intervention Trial (HIT): Study Protocol of a Randomized, Controlled, Parallel-Group Trial With Blinded Outcome Assessment.PDF

Background: Hyponatremia is the most common electrolyte disorder with a prevalence of up to 30% in hospitalized patients. In contrast to acute hyponatremia where the need for immediate treatment is well-recognized, chronic hyponatremia is often considered not clinically relevant. This is illustrated by reports showing that appropriate laboratory tests are ordered in Methods: This is a randomized (1:1 ratio) controlled, superiority, parallel-group international multi-center trial with blinded outcome assessment. In total 2,278 participants will be enrolled. Participants will be randomly assigned to undergo either targeted correction of plasma sodium levels or standard of care during hospitalization. The primary outcome is the combined risk of death or re-hospitalization within 30 days.Discussion: All data on hyponatremia and mortality are derived from observational studies and often lack methodologic robustness. Consequently, the direct impact of hyponatremia on mortality and rehospitalization risk is still debated, resulting in a clinical equipoise whether in-hospital chronic hyponatremia should be treated or not. Therefore, a randomized controlled trial is required to study whether targeted plasma sodium correction reduces the risk of mortality and rehospitalization associated with hyponatremia.Clinical Trial Registration:www.ClinicalTrials.gov, identifier: NCT03557957.</p